Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HealthEquity, Inc. - Common Stock (NQ:HQY)

98.42 +0.82 (+0.84%)
Streaming Delayed Price Updated: 12:13 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HealthEquity, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
If You Have Suffered Losses in HealthEquity, Inc. (NASDAQ: HQY) You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
Here's How Much You Would Have Made Owning HealthEquity Stock In The Last 10 Years
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY
From Pomerantz LLP
Via GlobeNewswire
How Is The Market Feeling About HealthEquity?
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of HealthEquity, Inc. - HQY
From Pomerantz LLP
Via GlobeNewswire
$100 Invested In HealthEquity 10 Years Ago Would Be Worth This Much Today
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY
From Pomerantz LLP
Via GlobeNewswire
If You Have Suffered Losses in HealthEquity, Inc. (NASDAQ: HQY) You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY
From Pomerantz LLP
Via GlobeNewswire
HealthEquity, Inc. Announcement: If You Have Suffered Losses in HealthEquity, Inc. (NASDAQ: HQY) You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY
From Pomerantz LLP
Via GlobeNewswire
Why HEALTHEQUITY INC (NASDAQ:HQY) Is a Standout High-Growth Stock in a Consolidation Phase.
Based on fundamental and technical analysis of NASDAQ:HQY we ask: Why HEALTHEQUITY INC (NASDAQ:HQY) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY
From Pomerantz LLP
Via GlobeNewswire
HealthEquity, Inc. Announcement: If You Have Suffered Losses in HealthEquity, Inc. (NASDAQ: HQY) You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY
From Pomerantz LLP
Via GlobeNewswire
Expert Outlook: HealthEquity Through The Eyes Of 8 Analysts
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY
From Pomerantz LLP
Via GlobeNewswire
HealthEquity, Inc. Announcement: If You Have Suffered Losses in HealthEquity, Inc. (NASDAQ: HQY) You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY
From Pomerantz LLP
Via GlobeNewswire
Rosen Law Firm Encourages HealthEquity, Inc. Investors to Inquire About Securities Class Action Investigation – HQY
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY
From Pomerantz LLP
Via GlobeNewswire
HealthEquity Earns Stock Upgrade Despite Fraud Concerns
HealthEquity's Q4 revenue beat estimates, but EPS missed. Raymond James upgraded the stock to Strong Buy, citing long-term growth despite fraud concerns. 
Via Benzinga
Topics Fraud
Exposures Legal
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside
Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target. 
Via Benzinga
This Cloudflare Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
$1000 Invested In HealthEquity 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Why HealthEquity Stock Was Sliding This Week
Via The Motley Fool
HealthEquity Stock Sees Biggest Drop In Over 3 Years On Disappointing Outlook — Retail Doesn't Feel It's All Doom And Gloom
CFO James Lucania said on the earnings call that fraud prevention efforts are ongoing, and service expenses are expected to remain elevated through the first half of fiscal 2026. 
Via Stocktwits
Topics Earnings Fraud
Exposures Financial Legal
4 Analysts Assess HealthEquity: What You Need To Know
Via Benzinga
HealthEquity's Long-Term Growth Intact Despite Short-Term Margin Pressures, Analyst Says
HealthEquity reported 19% revenue growth but missed Q4 EPS estimates. Analysts see earnings improving as cybersecurity costs ease and HSA growth continues. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.